- Open
- 2.55
- High
- 2.57
- Low
- 2.40
- Close
- 2.56
- Change
- -0.15 (-5.88%)
- Volume
- 3,848,666
⌘K
| 30 Jun 2026 | 07:00:07 | Change of Corporate Broker |
| 16 Jun 2026 | 12:33:17 | Result of AGM |
| 16 Jun 2026 | 07:00:08 | CIZ1B Test Approved For Clinical Use in USA |
| 12 Jun 2026 | 07:00:06 | Patent Granted in USA |
| 28 May 2026 | Annual Report and Accounts to 31 December 2025 | |
| 1 Sep 2025 | Financial Statements for the year ended 31 December 2024 | |
| 8 Jul 2025 | Annual Report for the year ended 31 December 2024 |
Cizzle Biotech received its initial funding from various sources including Yorkshire Cancer Research, White Rose Technology Seed Corn Fund, Finance Yorkshire Seedcorn LLP and Viking Members. The funds were invested in the project to aid the development of a prototype blood test, with the support of the management team.
| 30 Jun 2026 | 07:00:07 | Change of Corporate Broker |
| 16 Jun 2026 | 12:33:17 | Result of AGM |
| 16 Jun 2026 | 07:00:08 | CIZ1B Test Approved For Clinical Use in USA |
| 12 Jun 2026 | 07:00:06 | Patent Granted in USA |
| 28 May 2026 | Annual Report and Accounts to 31 December 2025 | |
| 1 Sep 2025 | Financial Statements for the year ended 31 December 2024 | |
| 8 Jul 2025 | Annual Report for the year ended 31 December 2024 |
Cizzle Biotech received its initial funding from various sources including Yorkshire Cancer Research, White Rose Technology Seed Corn Fund, Finance Yorkshire Seedcorn LLP and Viking Members. The funds were invested in the project to aid the development of a prototype blood test, with the support of the management team.
| 21 May 2026 |
| 07:51:13 |
| Notice of AGM |
| 21 May 2026 |
| Cizzle Biotechnology sets date for Annual General Meeting |
| 20 May 2026 | Cizzle Biotechnology targets early lung cancer detection market |
| 6 May 2026 | Cizzle Biotechnology to issue shares following £400,000 CLN conversion |
| 30 Apr 2026 | Cizzle Biotechnology 2025 results highlight licensing and clinical progress |
| 23 Feb 2026 | Cizzle Biotechnology secures additional US$3.5 million in guaranteed royalties as US launch nears |
| 23 Feb 2026 | Cizzle Biotechnology secures additional $3.5m in guaranteed royalty payments from US partner |
| 21 May 2026 |
| 07:51:13 |
| Notice of AGM |
| 21 May 2026 |
| Cizzle Biotechnology sets date for Annual General Meeting |
| 20 May 2026 | Cizzle Biotechnology targets early lung cancer detection market |
| 6 May 2026 | Cizzle Biotechnology to issue shares following £400,000 CLN conversion |
| 30 Apr 2026 | Cizzle Biotechnology 2025 results highlight licensing and clinical progress |
| 23 Feb 2026 | Cizzle Biotechnology secures additional US$3.5 million in guaranteed royalties as US launch nears |
| 23 Feb 2026 | Cizzle Biotechnology secures additional $3.5m in guaranteed royalty payments from US partner |
